FibroGen Stock Price, News & Analysis (NASDAQ:FGEN)

$42.40 0.45 (1.07 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$42.40
Today's Range$40.74 - $43.50
52-Week Range$19.25 - $60.15
Volume2.86 million shs
Average Volume581,447 shs
Market Capitalization$3.51 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.55

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:FGEN
CUSIPN/A
Phone+1-415-9781200

Debt

Debt-to-Equity Ratio0.16%
Current Ratio10.83%
Quick Ratio10.83%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$179.58 million
Price / Sales19.41
Cash FlowN/A
Price / CashN/A
Book Value$2.77 per share
Price / Book15.31

Profitability

Trailing EPS($2.03)
Net Income$-61,680,000.00
Net Margins-120.00%
Return on Equity-47.36%
Return on Assets-23.51%

Miscellaneous

Employees364
Outstanding Shares82,200,000

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen Inc (NASDAQ:FGEN) released its quarterly earnings results on Monday, August, 8th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.36 by $0.01. The biopharmaceutical company earned $89.28 million during the quarter, compared to analyst estimates of $80.58 million. FibroGen had a negative net margin of 120.00% and a negative return on equity of 47.36%. View FibroGen's Earnings History.

When will FibroGen make its next earnings announcement?

FibroGen is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for FibroGen.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

8 brokerages have issued 12 month price objectives for FibroGen's shares. Their forecasts range from $31.00 to $82.00. On average, they anticipate FibroGen's share price to reach $65.67 in the next year. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

  • Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder (Age 62)
  • Pat Cotroneo, Chief Financial Officer, Vice President - Finance (Age 53)
  • Frank H. Valone M.D., Senior Fellow, Clinical Development (Age 66)
  • K. Peony Yu M.D., Chief Medical Officer (Age 54)
  • Gerald Lema, Director
  • Jeffrey L. Edwards, Independent Director (Age 56)
  • Jeffrey William Henderson, Independent Director (Age 52)
  • Thomas F. Kearns Jr., Independent Director (Age 80)
  • Kalevi Kurkijarvi Ph.D., Independent Director (Age 65)

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (1.69%), JPMorgan Chase & Co. (1.28%), Eagle Asset Management Inc. (1.05%), Pinnacle Associates Ltd. (0.74%), Bank of New York Mellon Corp (0.47%) and Schwab Charles Investment Management Inc. (0.41%). Company insiders that own FibroGen stock include Frank H Md Valone, Gerald Lema, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr, Thomas F Kearns, Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Prudential Financial Inc., Candriam Luxembourg S.C.A., JPMorgan Chase & Co., ClariVest Asset Management LLC, Russell Investments Group Ltd., Handelsbanken Fonder AB and Sphera Funds Management LTD.. Company insiders that have sold FibroGen company stock in the last year include Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Jennison Associates LLC, Dimensional Fund Advisors LP, Bank of New York Mellon Corp, Columbus Circle Investors, Schwab Charles Investment Management Inc., EAM Investors LLC and Artal Group S.A.. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FibroGen stock can currently be purchased for approximately $42.40.

How big of a company is FibroGen?

FibroGen has a market capitalization of $3.51 billion and generates $179.58 million in revenue each year. The biopharmaceutical company earns $-61,680,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. FibroGen employs 364 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 Illinois St, SAN FRANCISCO, CA 94158-2509, United States. The biopharmaceutical company can be reached via phone at +1-415-9781200 or via email at [email protected]


MarketBeat Community Rating for FibroGen (FGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

FibroGen (NASDAQ:FGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.893.003.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $61.57$61.57$61.67$38.25
Price Target Upside: 13.92% upside13.92% upside19.51% upside53.31% upside

FibroGen (NASDAQ:FGEN) Consensus Price Target History

Price Target History for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017MizuhoReiterated RatingHold$61.00N/AView Rating Details
9/14/2017Stifel NicolausReiterated RatingBuy$80.00LowView Rating Details
9/12/2017Jefferies GroupReiterated RatingBuy$75.00LowView Rating Details
8/9/2017William BlairReiterated RatingOutperformMediumView Rating Details
8/8/2017Leerink SwannReiterated RatingOutperform -> Outperform$52.00 -> $82.00HighView Rating Details
8/8/2017CitigroupBoost Price TargetTop Pick$48.00 -> $65.00HighView Rating Details
7/21/2017Goldman Sachs GroupDowngradeBuy -> Neutral$31.00MediumView Rating Details
1/18/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

FibroGen (NASDAQ:FGEN) Earnings History and Estimates Chart

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.25)N/AView Earnings Details
8/7/2017Q2 2017($0.47)($0.48)$34.80 million$29.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

FibroGen (NASDAQ:FGEN) Earnings Estimates

2017 EPS Consensus Estimate: ($1.71)
2018 EPS Consensus Estimate: ($0.75)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.77)($0.48)($0.63)
Q2 20173($0.47)($0.43)($0.45)
Q3 20173($0.49)($0.23)($0.39)
Q4 20173($0.29)($0.15)($0.24)
Q1 20182($0.51)($0.48)($0.50)
Q2 20182($0.53)($0.51)($0.52)
Q3 20182($0.53)$1.00$0.24
Q4 20182($0.60)$0.66$0.03
(Data provided by Zacks Investment Research)

Dividends

Dividend History for FibroGen (NASDAQ:FGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

FibroGen (NASDAQ FGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 57.43%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/14/2017K Peony YuInsiderSell2,851$43.70$124,588.70View SEC Filing  
12/14/2017Thomas B NeffCEOSell18,900$42.71$807,219.00View SEC Filing  
12/12/2017Kalevi KurkijarviDirectorSell12,000$44.45$533,400.00View SEC Filing  
12/11/2017Pat CotroneoVPSell2,851$46.00$131,146.00View SEC Filing  
12/4/2017Gerald LemaDirectorBuy3,500$46.70$163,450.00View SEC Filing  
12/1/2017Jorma RouttiDirectorSell12,000$47.25$567,000.00View SEC Filing  
11/17/2017Kalevi KurkijarviDirectorSell2,000$46.65$93,300.00View SEC Filing  
11/16/2017Thomas B NeffCEOSell18,900$46.60$880,740.00View SEC Filing  
11/15/2017Thomas F Kearns JrDirectorSell18,000$45.22$813,960.00View SEC Filing  
11/6/2017K Peony YuInsiderSell7,500$55.37$415,275.00View SEC Filing  
10/31/2017Thomas B NeffCEOSell38,636$56.13$2,168,638.68View SEC Filing  
10/17/2017Kalevi KurkijarviDirectorSell2,000$52.24$104,480.00View SEC Filing  
10/17/2017Thomas B NeffCEOSell38,636$55.02$2,125,752.72View SEC Filing  
10/16/2017Thomas B NeffCEOSell18,900$54.83$1,036,287.00View SEC Filing  
10/4/2017K Peony YuInsiderSell15,000$60.00$900,000.00View SEC Filing  
10/3/2017Thomas B NeffCEOSell38,636$55.09$2,128,457.24View SEC Filing  
10/2/2017K Peony YuInsiderSell40,000$54.63$2,185,200.00View SEC Filing  
10/2/2017Thomas B NeffCEOSell18,900$54.45$1,029,105.00View SEC Filing  
9/20/2017Thomas B NeffCEOSell38,636$53.46$2,065,480.56View SEC Filing  
9/18/2017Kalevi KurkijarviDirectorSell4,000$46.65$186,600.00View SEC Filing  
9/14/2017K Peony YuInsiderSell2,851$51.00$145,401.00View SEC Filing  
9/14/2017Thomas B NeffCEOSell38,636$51.67$1,996,322.12View SEC Filing  
9/13/2017Rory B RiggsDirectorSell25,000$51.92$1,298,000.00View SEC Filing  
9/13/2017Thomas B NeffCEOSell18,900$51.29$969,381.00View SEC Filing  
9/11/2017Pat CotroneoVPSell2,851$49.45$140,981.95View SEC Filing  
9/1/2017Jorma RouttiDirectorSell12,000$47.36$568,320.00View SEC Filing  
8/29/2017Thomas B NeffCEOSell38,636$43.73$1,689,552.28View SEC Filing  
8/28/2017Thomas B NeffCEOSell18,900$43.04$813,456.00View SEC Filing  
8/21/2017K Peony YuInsiderSell7,500$41.03$307,725.00View SEC Filing  
8/17/2017Kalevi KurkijarviDirectorSell2,000$40.74$81,480.00View SEC Filing  
8/8/2017K Peony YuInsiderSell37,500$50.58$1,896,750.00View SEC Filing  
8/8/2017Pat CotroneoVPSell95,000$50.61$4,807,950.00View SEC Filing  
8/2/2017Pat CotroneoVPSell28,346$33.97$962,913.62View SEC Filing  
8/1/2017K Peony YuInsiderSell10,000$33.48$334,800.00View SEC Filing  
7/25/2017Thomas B NeffCEOSell38,636$35.09$1,355,737.24View SEC Filing  
7/24/2017Thomas B NeffCEOSell18,900$35.06$662,634.00View SEC Filing  
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.00View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.68View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.00View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.72View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.40View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.00View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.00View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.56View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.00View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.20View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.00View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.12View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.00View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.00View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.44View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.12View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.24View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.00View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.52View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.00View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.84View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.00View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.08View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.42View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.00View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.30View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.52View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.52View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.52View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.40View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.26View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.42View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.48View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

FibroGen (NASDAQ FGEN) News Headlines

Source:
DateHeadline
K Peony Yu Sells 2,851 Shares of FibroGen Inc (FGEN) StockK Peony Yu Sells 2,851 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - December 15 at 9:22 PM
Thomas B. Neff Sells 18,900 Shares of FibroGen Inc (FGEN) StockThomas B. Neff Sells 18,900 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - December 15 at 8:52 PM
ETFs with exposure to FibroGen, Inc. : December 15, 2017ETFs with exposure to FibroGen, Inc. : December 15, 2017
finance.yahoo.com - December 15 at 5:56 PM
-$0.28 Earnings Per Share Expected for FibroGen Inc (FGEN) This Quarter-$0.28 Earnings Per Share Expected for FibroGen Inc (FGEN) This Quarter
www.americanbankingnews.com - December 15 at 11:06 AM
FibroGen Inc (FGEN) VP Pat Cotroneo Sells 2,851 SharesFibroGen Inc (FGEN) VP Pat Cotroneo Sells 2,851 Shares
www.americanbankingnews.com - December 13 at 9:50 PM
FibroGen Inc (FGEN) Director Sells $533,400.00 in StockFibroGen Inc (FGEN) Director Sells $533,400.00 in Stock
www.americanbankingnews.com - December 13 at 9:28 PM
Comparing FibroGen (FGEN) and Celyad (CYAD)Comparing FibroGen (FGEN) and Celyad (CYAD)
www.americanbankingnews.com - December 10 at 5:20 PM
FibroGen (FGEN) Downgraded by BidaskClub to SellFibroGen (FGEN) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - December 9 at 6:32 PM
Analysts Predict 22% Upside For PBE - NasdaqAnalysts Predict 22% Upside For PBE - Nasdaq
www.nasdaq.com - December 7 at 5:46 PM
Insider Buying: FibroGen, Inc (FGEN) Director Acquires 3,500 Shares of StockInsider Buying: FibroGen, Inc (FGEN) Director Acquires 3,500 Shares of Stock
www.americanbankingnews.com - December 5 at 9:30 PM
FibroGen is Now Oversold (FGEN)FibroGen is Now Oversold (FGEN)
www.nasdaq.com - December 5 at 10:11 AM
Jorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) StockJorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) Stock
www.americanbankingnews.com - December 4 at 11:22 PM
FibroGen (FGEN) Cut to "Sell" at ValuEngineFibroGen (FGEN) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - December 3 at 2:20 PM
Zacks: Brokerages Anticipate FibroGen, Inc (FGEN) Will Post Quarterly Sales of $45.37 MillionZacks: Brokerages Anticipate FibroGen, Inc (FGEN) Will Post Quarterly Sales of $45.37 Million
www.americanbankingnews.com - November 29 at 10:32 AM
Zacks: Brokerages Anticipate FibroGen, Inc (FGEN) to Announce -$0.28 EPSZacks: Brokerages Anticipate FibroGen, Inc (FGEN) to Announce -$0.28 EPS
www.americanbankingnews.com - November 27 at 5:26 AM
FibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from AnalystsFibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 23 at 1:52 AM
FibroGen, Inc (FGEN) Director Sells $93,300.00 in StockFibroGen, Inc (FGEN) Director Sells $93,300.00 in Stock
www.americanbankingnews.com - November 20 at 10:54 PM
ETFs with exposure to FibroGen, Inc. : November 20, 2017ETFs with exposure to FibroGen, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 7:23 PM
FibroGen Sees Unusually Large Options Volume (FGEN)FibroGen Sees Unusually Large Options Volume (FGEN)
www.americanbankingnews.com - November 18 at 2:02 AM
FibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 SharesFibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 Shares
www.americanbankingnews.com - November 17 at 8:10 PM
Thomas F. Kearns, Jr. Sells 18,000 Shares of FibroGen, Inc (FGEN) StockThomas F. Kearns, Jr. Sells 18,000 Shares of FibroGen, Inc (FGEN) Stock
www.americanbankingnews.com - November 17 at 8:10 PM
FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
finance.yahoo.com - November 13 at 10:07 AM
FY2017 EPS Estimates for FibroGen, Inc (FGEN) Increased by AnalystFY2017 EPS Estimates for FibroGen, Inc (FGEN) Increased by Analyst
www.americanbankingnews.com - November 13 at 3:36 AM
William Blair Research Analysts Increase Earnings Estimates for FibroGen, Inc (FGEN)William Blair Research Analysts Increase Earnings Estimates for FibroGen, Inc (FGEN)
www.americanbankingnews.com - November 13 at 3:36 AM
FibroGen, Inc (FGEN) to Post FY2017 Earnings of ($1.75) Per Share, Jefferies Group ForecastsFibroGen, Inc (FGEN) to Post FY2017 Earnings of ($1.75) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 13 at 3:36 AM
Edited Transcript of FGEN earnings conference call or presentation 8-Nov-17 10:00pm GMTEdited Transcript of FGEN earnings conference call or presentation 8-Nov-17 10:00pm GMT
finance.yahoo.com - November 10 at 4:25 PM
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017
finance.yahoo.com - November 10 at 4:25 PM
Q3 2018 EPS Estimates for FibroGen, Inc Raised by William Blair (FGEN)Q3 2018 EPS Estimates for FibroGen, Inc Raised by William Blair (FGEN)
www.americanbankingnews.com - November 10 at 4:20 PM
OTIC Data Music To Ears, Apellis IPO Opens Today, CAPR High On HOPE - NasdaqOTIC Data Music To Ears, Apellis IPO Opens Today, CAPR High On HOPE - Nasdaq
www.nasdaq.com - November 9 at 3:24 AM
Commit To Buy FibroGen At $40, Earn 13.5% Annualized Using Options - NasdaqCommit To Buy FibroGen At $40, Earn 13.5% Annualized Using Options - Nasdaq
www.nasdaq.com - November 9 at 3:24 AM
FibroGen Reports Third Quarter 2017 Financial Results Nasdaq:FGEN - GlobeNewswire (press release)FibroGen Reports Third Quarter 2017 Financial Results Nasdaq:FGEN - GlobeNewswire (press release)
globenewswire.com - November 9 at 3:23 AM
Is It Too Late To Buy FibroGen Inc (FGEN)?Is It Too Late To Buy FibroGen Inc (FGEN)?
finance.yahoo.com - November 9 at 3:23 AM
FibroGen, Inc. to Host Earnings CallFibroGen, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 3:23 AM
FibroGen Reports Third Quarter 2017 Financial ResultsFibroGen Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 3:23 AM
FibroGen reports 3Q lossFibroGen reports 3Q loss
finance.yahoo.com - November 9 at 3:23 AM
ETFs with exposure to FibroGen, Inc. : November 8, 2017ETFs with exposure to FibroGen, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 3:23 AM
FibroGen, Inc (FGEN) Insider Sells $415,275.00 in StockFibroGen, Inc (FGEN) Insider Sells $415,275.00 in Stock
www.americanbankingnews.com - November 8 at 9:22 PM
 Brokerages Anticipate FibroGen, Inc (FGEN) to Post -$0.37 Earnings Per Share Brokerages Anticipate FibroGen, Inc (FGEN) to Post -$0.37 Earnings Per Share
www.americanbankingnews.com - November 8 at 3:54 PM
Implied FBT Analyst Target Price: $156Implied FBT Analyst Target Price: $156
www.nasdaq.com - November 6 at 8:33 PM
Astellas, FibroGen (FGEN) Announce Positive Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease - StreetInsider.comAstellas, FibroGen (FGEN) Announce Positive Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease - StreetInsider.com
www.streetinsider.com - November 2 at 12:51 AM
Insider Selling: FibroGen, Inc (FGEN) CEO Sells 38,636 Shares of StockInsider Selling: FibroGen, Inc (FGEN) CEO Sells 38,636 Shares of Stock
www.americanbankingnews.com - November 1 at 8:50 PM
Astellas, FibroGen (FGEN) Announce Positive Japan Phase 3 Trial for Roxadustat in Chronic Kidney DiseaseAstellas, FibroGen (FGEN) Announce Positive Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease
www.streetinsider.com - October 31 at 7:49 PM
FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017 - GlobeNewswire (press release)FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017 - GlobeNewswire (press release)
globenewswire.com - October 31 at 12:33 AM
FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017
feeds.benzinga.com - October 30 at 8:49 PM
FibroGen, Inc (FGEN) Set to Announce Earnings on MondayFibroGen, Inc (FGEN) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 30 at 9:38 AM
FibroGen, Inc (FGEN) Given Average Rating of "Buy" by BrokeragesFibroGen, Inc (FGEN) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 29 at 1:52 AM
Reviewing FibroGen (FGEN) and Its PeersReviewing FibroGen (FGEN) and Its Peers
www.americanbankingnews.com - October 26 at 9:20 PM
ETFs with exposure to FibroGen, Inc. : October 24, 2017ETFs with exposure to FibroGen, Inc. : October 24, 2017
finance.yahoo.com - October 24 at 11:57 PM
Zacks: Analysts Anticipate FibroGen, Inc (FGEN) Will Announce Quarterly Sales of $41.34 MillionZacks: Analysts Anticipate FibroGen, Inc (FGEN) Will Announce Quarterly Sales of $41.34 Million
www.americanbankingnews.com - October 21 at 3:52 AM
FibroGen (FGEN) Reports China FDA Acceptance of Roxadustat New Drug Application (NDA) - StreetInsider.comFibroGen (FGEN) Reports China FDA Acceptance of Roxadustat New Drug Application (NDA) - StreetInsider.com
www.streetinsider.com - October 19 at 7:28 PM

SEC Filings

FibroGen (NASDAQ:FGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

FibroGen (NASDAQ:FGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

FibroGen (NASDAQ FGEN) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.